Relaxin inhibits cardiac fibrosis and endothelial–mesenchymal transition via the Notch pathway [Corrigendum]
Zhou X, Chen X, Cai JJ, et al. Drug Des Devel Ther. 2015;9: 4599–4611. On page 4600, the product type and source of the relaxin used in these experiments was missed from the ‘Materials and methods’ section. Under the subheading ‘Rat model of cardiac fibrosis&a...
Saved in:
Main Authors: | Zhou X (Author), Chen X (Author), Cai JJ (Author), Chen LZ (Author), Gong YS (Author), Wang LX (Author), Gao Z (Author), Zhang HQ (Author), Huang WJ (Author), Zhou H (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2017-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Relaxin inhibits cardiac fibrosis and endothelial–mesenchymal transition via the Notch pathway
by: Zhou X, et al.
Published: (2015) -
Trimetazidine Reduces Cardiac Fibrosis in Rats by Inhibiting NOX2-Mediated Endothelial-to-Mesenchymal Transition
by: Chen X, et al.
Published: (2022) -
Spirolactone provides protection from renal fibrosis by inhibiting the endothelial–mesenchymal transition in isoprenaline-induced heart failure in rats
by: Zhou H, et al.
Published: (2016) -
Relaxin treatment stimulates the differentiation of mesenchymal stem cells into osteoblasts
by: Lina M. Escobar, et al.
Published: (2023) -
Roles of TGF-β Signals in Endothelial-Mesenchymal Transition during Cardiac Fibrosis
by: Yasuhiro Yoshimatsu, et al.
Published: (2011)